{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:44:34Z","timestamp":1794635074742,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40257-021-00618-3","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T05:11:32Z","timestamp":1629263492000},"page":"693-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program"],"prefix":"10.1007","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct02780167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03349060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03575871","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03720470","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03627767","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03422822","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Nosbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin M.","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem A.","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5016-5768","authenticated-orcid":false,"given":"Susan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"issue":"1","key":"618_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22 e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"618_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41687-019-0128-z","volume":"3","author":"L Newton","year":"2019","unstructured":"Newton L, DeLozier AM, Griffiths PC, Hill JN, Hudgens S, Symonds T, et al. Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep Outcomes. 2019;3(1):42.","journal-title":"J Patient Rep Outcomes."},{"issue":"8","key":"618_CR3","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.jaip.2019.05.055","volume":"7","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States Adults. J Allergy Clin Immunol Pract. 2019;7(8):2699-706.e7.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"618_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","volume":"119","author":"PP Vakharia","year":"2017","unstructured":"Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52 e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"618_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","volume":"69","author":"N Katoh","year":"2020","unstructured":"Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69(3):356\u201369.","journal-title":"Allergol Int"},{"issue":"6","key":"618_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"2","key":"618_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"H He","year":"2019","unstructured":"He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181\u201392.","journal-title":"Am J Clin Dermatol"},{"key":"618_CR8","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"12","key":"618_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"618_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"618_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"The Lancet"},{"issue":"12","key":"618_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"864","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;864(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"12","key":"618_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","volume":"80","author":"M Harigai","year":"2020","unstructured":"Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache? Drugs. 2020;80(12):1183\u2013201.","journal-title":"Drugs"},{"issue":"4","key":"618_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343.","journal-title":"Nat Rev Rheumatol"},{"issue":"6\u20137","key":"618_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00439-020-02126-6","volume":"139","author":"S Boisson-Dupuis","year":"2020","unstructured":"Boisson-Dupuis S. The monogenic basis of human tuberculosis. Hum Genet. 2020;139(6\u20137):1001\u20139.","journal-title":"Hum Genet"},{"issue":"4","key":"618_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s10875-019-00637-0","volume":"39","author":"AK Jindal","year":"2019","unstructured":"Jindal AK, Suri D, Guleria S, Rawat A, Garg S, Bal A, et al. Recurrent salmonella typhi infection and autoimmunity in a young boy with complete IL-12 receptor \u03b21 deficiency. J Clin Immunol. 2019;39(4):358\u201362.","journal-title":"J Clin Immunol"},{"issue":"4","key":"618_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/imm.12362","volume":"143","author":"NL Smith","year":"2014","unstructured":"Smith NL, Denning DW. Clinical implications of interferon-gamma genetic and epigenetic variants. Immunology. 2014;143(4):499\u2013511.","journal-title":"Immunology"},{"key":"618_CR18","unstructured":"ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A [Internet]. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [Updated October 24 1994]. https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf. Accessed 1 April 2021."},{"issue":"3","key":"618_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 1","key":"618_CR20","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(suppl 1):i34\u201342.","journal-title":"Rheumatology (Oxford)"},{"key":"618_CR21","doi-asserted-by":"publisher","first-page":"1759720X2093605","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"618_CR22","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","volume":"9","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061.","journal-title":"Front Immunol"},{"issue":"2","key":"618_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00018-015-2062-4","volume":"73","author":"AT Waickman","year":"2016","unstructured":"Waickman AT, Park JY, Park JH. The common gamma-chain cytokine receptor: tricks-and-treats for T cells. Cell Mol Life Sci. 2016;73(2):253\u201369.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"618_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","volume":"13","author":"M Gadina","year":"2001","unstructured":"Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol. 2001;13(3):363\u201373.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"618_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"618_CR26","doi-asserted-by":"publisher","first-page":"ofaa005-ofaa","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005-ofaa.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"618_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929\u201336.","journal-title":"Gastroenterology"},{"issue":"2","key":"618_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1067\/S0190-9622(03)00896-X","volume":"49","author":"A Wollenberg","year":"2003","unstructured":"Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol. 2003;49(2):198\u2013205.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"618_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaci.2009.05.020","volume":"124","author":"LA Beck","year":"2009","unstructured":"Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin J, Gallo R, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"618_CR30","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","volume":"133","author":"S Khattri","year":"2014","unstructured":"Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133(6):1626\u201334.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"618_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","volume":"128","author":"S Tintle","year":"2011","unstructured":"Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):583-93 e1-4.","journal-title":"J Allergy Clin Immunol"},{"key":"618_CR32","unstructured":"Olumiant. Prescribing information. Eli Lilly and Company; 2020."},{"issue":"6","key":"618_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2018-06-854935","volume":"132","author":"KM Hoffmeister","year":"2018","unstructured":"Hoffmeister KM. TPO-logy accepted. Blood. 2018;132(6):555\u20137.","journal-title":"Blood"},{"issue":"9","key":"618_CR34","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","volume":"98","author":"A Kaser","year":"2001","unstructured":"Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720\u20135.","journal-title":"Blood"},{"issue":"7","key":"618_CR35","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/psp4.12419","volume":"8","author":"S Koride","year":"2019","unstructured":"Koride S, Nayak S, Banfield C, Peterson MC. Evaluating the role of Janus kinase pathways in platelet homeostasis using a systems modeling approach. CPT Pharmacometr Syst Pharmacol. 2019;8(7):478\u201388.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"14","key":"618_CR36","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2014-03-560441","volume":"124","author":"SC Meyer","year":"2014","unstructured":"Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, et al. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014;124(14):2280\u20134.","journal-title":"Blood"},{"issue":"3","key":"618_CR37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","volume":"61","author":"ML Vazquez","year":"2018","unstructured":"Vazquez ML, Kaila N, Strohbach JW, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem. 2018;61(3):1130\u201352.","journal-title":"J Med Chem"},{"issue":"9","key":"618_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1074-7613(94)80014-6","volume":"1","author":"A Bernad","year":"1994","unstructured":"Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1994;1(9):725\u201331.","journal-title":"Immunity"},{"issue":"24","key":"618_CR39","doi-asserted-by":"publisher","first-page":"9035","DOI":"10.1073\/pnas.84.24.9035","volume":"84","author":"K Ikebuchi","year":"1987","unstructured":"Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA. 1987;84(24):9035\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"618_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0320-5","volume":"51","author":"R Tie","year":"2019","unstructured":"Tie R, Li H, Cai S, Liang Z, Shan W, Wang B, et al. Interleukin-6 signaling regulates hematopoietic stem cell emergence. Exp Mol Med. 2019;51(10):1\u201312.","journal-title":"Exp Mol Med"},{"key":"618_CR41","unstructured":"Actemra. Prescribing information. Genentech Inc; 2020."},{"issue":"1 Pt B","key":"618_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.imlet.2014.06.016","volume":"162","author":"T Pritz","year":"2014","unstructured":"Pritz T, Weinberger B, Grubeck-Loebenstein B. The aging bone marrow and its impact on immune responses in old age. Immunol Lett. 2014;162(1 pt B):310\u20135.","journal-title":"Immunol Lett"},{"issue":"1","key":"618_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"618_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(7):1042\u201355.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"618_CR45","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s40257-021-00638-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00618-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00618-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00618-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T05:37:36Z","timestamp":1651642656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00618-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00618-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-021-00638-z","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"16 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed video abstract was retrospectively added to this publication.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-021-00638-z","URL":"https:\/\/doi.org\/10.1007\/s40257-021-00638-z","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"<i>E. L. Simpson<\/i> reports grants from Pfizer Inc., Eli Lilly, Kyowa Kirin, LEO Pharma, Merck, and Regeneron and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron, and Sanofi Genzyme. <i>J. I. Silverberg<\/i> is an investigator for AbbVie, Celgene, Eli Lilly, GSK, Kiniksa, LEO Pharma, Menlo Therapeutics, Realm Therapeutics, Regeneron, Roche, and Sanofi; a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Asana Biosciences, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Glenmark, Incyte, Kiniksa, LEO Pharma, MedImmune, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; a speaker for Regeneron and Sanofi; and is on advisory boards for Pfizer Inc., Dermira, LEO Pharma, and Menlo Therapeutics. <i>A.<\/i>\u00a0<i>Nosbaum<\/i> is an investigator for AbbVie, Eli Lilly, Incyte, LEO Pharma, Novartis, and Sanofi; a consultant for Pfizer Inc., AbbVie, Eli Lilly, Galderma, LEO Pharma, Novartis, and Sanofi; a speaker for AbbVie, Regeneron, and Sanofi; and is on advisory boards for Pfizer Inc., AbbVie, LEO Pharma, and Sanofi. <i>K. L. Winthrop<\/i> reports research grants from Bristol Myers Squibb and consultant honorarium from Pfizer, Eli Lilly, Bristol Myers Squibb, UCB, AbbVie, Gilead, Roche, Novartis, Regeneron, and Sanofi. <i>E. Guttman-Yassky<\/i> is an advisory board member for Celgene, Dermira, Galderma, Glenmark, Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Stiefel\/GlaxoSmithKline, Vitae, and Asana Biosciences (honorarium); consultant for AbbVie, Anacor, Celgene, Dermira, Galderma, Glenmark, LEO Pharma, Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Stiefel\/GlaxoSmithKline, Vitae, Mitsubishi Tanabe, Eli Lilly, Asana Biosciences, Kiowa Kirin, and Almirall (honorarium); and investigator for Celgene, LEO Pharma, Medimmune, Regeneron, and Eli Lilly (grants to institution). <i>K. M. Hoffmeister<\/i> has received honoraria as consultant from Pfizer. <i>A. Egeberg<\/i> has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and\/or speaker from AbbVie, Almirall, LEO Pharma, Gal\u00e1pagos NV, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol Myers Squibb, and Janssen Pharmaceuticals. <i>H. Valdez<\/i>, <i>M. Zhang<\/i>, <i>S. A. Farooqui<\/i>, <i>W. Romero<\/i>, <i>A. J. Thorpe<\/i>, <i>R.<\/i>\u00a0<i>Rojo<\/i>, and <i>S. Johnson<\/i> are employees of and shareholders in Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest and financial disclosures"}},{"value":"Ethics approval was obtained for individual studies included in this integrated safety analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants of the individual studies included in this integrated safety analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Upon request, and subject to certain criteria, conditions, and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"EGY, AE, HV, MZ, WR, AJT, RR, and SJ contributed to the conceptualization and design of the analysis. ELS, AN, KLW, KMH, AE, MZ, WR, AJT, and SJ performed or supported the data analysis. All authors contributed to the data interpretation, critically reviewed the manuscript and approved the submitted version.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}